Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...

Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...

Parasites are an often-overlooked threat in pet care, especially for cats, as infestations can cause serious health issues ...

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

The increasing demand for gene therapy and CRISPR technology increases the genome engineering.Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Introspective Market Research is pleased to announce the ...

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

Boehringer will leverage ExpressionEdits' Genetic Syntax Engine which generates optimized introns to increase protein expression.

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...

Planet Fitness, Inc. , one of the largest and fastest-growing franchisors and operators of fitness centers with more members than any other fitness brand, announced today that it has realigned its ...

DOC, an Italian pharmaceutical company specialized in the marketing of generic drugs, expands its strategy by broadening its business lines and defines a new vision for the future, reflected in a new ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.